Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Assets (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Non-Current Assets data on record, last reported at $64.1 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 32.03% year-over-year to $64.1 million; the TTM value through Dec 2025 reached $313.3 million, up 38.27%, while the annual FY2025 figure was $64.1 million, 32.03% down from the prior year.
  • Non-Current Assets reached $64.1 million in Q4 2025 per ACRS's latest filing, down from $74.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $102.7 million in Q2 2023 and bottomed at $11.1 million in Q3 2022.
  • Average Non-Current Assets over 5 years is $55.9 million, with a median of $48.4 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: crashed 80.84% in 2022, then surged 761.61% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $46.2 million in 2021, then crashed by 50.09% to $23.0 million in 2022, then skyrocketed by 197.44% to $68.5 million in 2023, then soared by 37.68% to $94.4 million in 2024, then crashed by 32.03% to $64.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $64.1 million in Q4 2025, $74.9 million in Q3 2025, and $84.9 million in Q2 2025.